The history of dopamine and levodopa in the treatment of Parkinson's disease (Q22252881)

Europe PubMed Central

title

The history of dopamine and levodopa in the treatment of Parkinson's disease (English)

0 references

1 reference

1 reference

1 reference

1

Stanley Fahn

Stanley

Fahn

1 reference

PubMed

PubMed publication ID

18781671

Chemical structure and sympathomimetic action of amines

7 February 2023

language of work or name

English

0 references

publication date

2008

0 references

published in

Movement Disorders

0 references

volume

23

0 references

issue

S3

0 references

page(s)

S497-S508

0 references

cites work

1 reference

Treatment of Parkinsonism With Levodopa

21 January 2018

1 reference

Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

21 January 2018

1 reference

Levodopa-induced myoclonus

21 January 2018

1 reference

Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease

21 January 2018

1 reference

Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators

21 January 2018

1 reference

Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral Inhibitor

21 January 2018

1 reference

Carbidopa in Parkinson disease and in nausea and vomiting of levodopa

21 January 2018

1 reference

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

21 January 2018

1 reference

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.

21 January 2018

1 reference

Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).

21 January 2018

1 reference

Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations

21 January 2018

1 reference

Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.

21 January 2018

1 reference

Considerations in the management of parkinsonism

21 January 2018

1 reference

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

7 January 2021

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

1 reference

7 January 2021

Dihydroxyphenylalanine in extrapyramidal disease.

1 reference

7 January 2021

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

1 reference

7 January 2021

Dopamine miracle: from brain homogenate to dopamine replacement

1 reference

7 January 2021

Striatal inhomogeneities and basal ganglia function

1 reference

7 January 2021

Effects of tolcapone in Parkinson's patients taking L‐dihydroxyphenylalanine/carbidopa and selegiline

1 reference

7 January 2021

THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY

1 reference

7 January 2021

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

1 reference

7 January 2021

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

1 reference

7 January 2021

1 reference

7 January 2021

Fermentativer Abbau von l-Dioxyphenylalanin (Dopa) durch Niere

1 reference

7 January 2021

[On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6]

1 reference

7 January 2021

L-DOPA: From a biologically inactive amino acid to a successful therapeutic agent

1 reference

7 January 2021

Distribution of catechol compounds in human brain

1 reference

7 January 2021

DEMONSTRATION AND MAPPING OUT OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS.

1 reference

7 January 2021

Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease

1 reference

7 January 2021

Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders

1 reference

7 January 2021

Newer Medical Treatments in Parkinsonism

1 reference

7 January 2021

The contribution of basal ganglia to limb control

1 reference

7 January 2021

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

1 reference

7 January 2021

Methyldopa or methyldopahydrazine as levodopa synergists.

1 reference

7 January 2021

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

1 reference

7 January 2021

"Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease

1 reference

7 January 2021

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

1 reference

7 January 2021

Intracellular distribution of catecholamines in the brain

1 reference

7 January 2021

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

1 reference

7 January 2021

Catechol compounds in rat tissues and in brains of different animals

1 reference

7 January 2021

Linkage mapping of dopa–responsive dystonia (DRD) to chromosome 14q

1 reference

7 January 2021

Was leistet L-Dopa bei der Behandlung der Parkinson-Akinese?*

1 reference

7 January 2021

ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)

1 reference

7 January 2021

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

7 January 2021

Modification of Parkinsonism--chronic treatment with L-dopa

1 reference

7 January 2021

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

7 January 2021

Levodopa and the progression of Parkinson's disease

1 reference

7 January 2021

Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles.

1 reference

7 January 2021

INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM

1 reference

7 January 2021

Controlled-Release Carbidopa/Levodopa in the Treatment of Parkinsonism

1 reference

7 January 2021

Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations.

1 reference

7 January 2021

Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease

1 reference

7 January 2021

Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study

1 reference

7 January 2021

A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

1 reference

7 January 2021

Treatment of Parkinson's syndrome with L-dopa. A double blind study

1 reference

7 January 2021

Serotonin release as a possible mechanism of reserpine action

1 reference

7 January 2021

On the presence of 3-hydroxytyramine in brain

1 reference

7 January 2021

Controlled release levodopa treatment of motor fluctuations in Parkinson's disease

1 reference

7 January 2021

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease

1 reference

7 January 2021

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

1 reference

7 January 2021

Open study of Madopar HBS, a new formulation of levodopa with benserazide, in 13 patients with Parkinson's disease and 'on-off' fluctuations

1 reference

7 January 2021

Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy

1 reference

7 January 2021

Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability

1 reference

7 January 2021

A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease

1 reference

7 January 2021

Selegiline slows the progression of the symptoms of Parkinson disease

1 reference

7 January 2021

Dopamine metabolism in Parkinson's disease.

1 reference

7 January 2021

"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine

1 reference

7 January 2021

Evidence to support early levodopa therapy in Parkinson disease

1 reference

7 January 2021

Clinical and biochemical studies with controlled-release levodopa/carbidopa

1 reference

7 January 2021

Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease

1 reference

7 January 2021

Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

1 reference

7 January 2021

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

7 January 2021

Molecular genetics of dopa-responsive dystonia

1 reference

7 January 2021

Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

1 reference

7 January 2021

Concentration and distribution of "encephalin" in the brain of humans and animals.

1 reference

7 January 2021